98%
921
2 minutes
20
Purpose: To construct the albumin-bilirubin (ALBI) grade and the Child-Turcotte-Pugh (CTP) score based on nomograms, as well as to develop an artificial neural network (ANN) to compare the prognostic performance of the 2 scores for hepatocellular carcinoma (HCC) that has undergone transarterial chemoembolization.
Materials And Methods: This multicentric retrospective study included patients with HCC who underwent transarterial chemoembolization monotherapy as an initial treatment at 4 institutions between January 2008 and December 2016. In the training cohort, significant risk factors associated with overall survival (OS) were identified by univariate and multivariate analyses. The prognostic nomograms and ANN were established and then validated in 2 validation cohorts.
Results: A total of 838 patients (548, 115, and 175 in the training cohort and validation cohorts 1 and 2, respectively) were included. The median OS was 10.4, 15.7, and 9.2 months in the training cohort and validation cohorts 1 and 2, respectively. In the training cohort, both ALBI grade and CTP score were identified as significant risk factors. The ALBI grade and CTP score based on nomograms were established separately and showed similar prognostic performance when assessed externally in validation cohorts (C-index in validation cohort 1: 0.823 vs 0.802, P = .417; in validation cohort 2: 0.716 vs 0.729, P = .793). ANN showed that ALBI grade had higher importance on survival prediction than CTP score.
Conclusions: ALBI grade performs at least no worse than CTP score regarding survival prediction for HCC receiving transarterial chemoembolization. Considering the easy application, ALBI grade has the potential to be regarded as an alternative to CTP score.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jvir.2018.08.026 | DOI Listing |
Radiol Phys Technol
September 2025
Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, Ishikawa, 920-0942, Japan.
This study evaluated whether temporal changes from the dynamic late phase to the hepatobiliary phase using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid supported liver tumor classification. A total of 147 patients with 165 lesions (hepatocellular carcinoma [HCC], metastases, and hemangiomas) underwent 3.0 T MRI.
View Article and Find Full Text PDFActa Med Philipp
July 2025
Division of Internal Medicine, National Kidney and Transplant Institute, Quezon City, Philippines.
Background And Objective: Patients with liver cirrhosis have an increased risk for poor postoperative outcomes after non-hepatic surgery, with liver dysfunction being the most important predictor of poor outcomes. This study aims to determine the association of the albumin-bilirubin (ALBI) grade, aspartate aminotransferase-platelet ratio index (APRI) score, and ALBI-APRI score with postoperative outcomes among cirrhotic patients who have undergone non-hepatic surgery.
Methods: This was a retrospective cohort study involving 34 patients.
In Vivo
August 2025
Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Türkiye.
Background/aim: Cholangiocarcinoma (CCA) is the second most frequently occurring primary malignant tumor of the liver, characterized by poor survival due to late diagnosis and limited treatment options. The albumin-bilirubin (ALBI) and platelet-ALBI (PALBI) scores, which reflect liver function and inflammation, have emerged as potential prognostic markers in hepatocellular carcinoma (HCC). Their prognostic significance in CCA, however, remains less established.
View Article and Find Full Text PDFCancer Med
September 2025
Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
Background/aim: The global aging population includes an increasing number of elderly patients with hepatocellular carcinoma (HCC). This study aimed to clarify the real-world outcomes, prognostic factors, and appropriate administration indicators for immunotherapy in elderly HCC patients.
Methods: This retrospective multicenter study analyzed 286 patients with unresectable HCC who received first-line immunotherapy (atezolizumab-bevacizumab or durvalumab-tremelimumab) between November 2020 and January 2024.
BMC Cancer
August 2025
Division of Gastroenterology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
Background: The factors associated with extrahepatic recurrence (EHR) after curative resection for hepatocellular carcinoma (HCC) have rarely been investigated. This study examined the pre- and postoperative predictors of EHR after curative resection in HCC patients over a ten-year follow-up period.
Methods: A retrospective review was conducted on treatment-naïve HCC patients who underwent curative resection between 2004 and 2019 at four tertiary hospitals in South Korea.